Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Clinical Services: To outsource or To Not Outsource, That Is the Question

When providers think of purchased services, their minds typically go to facility support, IT, and ancillary services. However, this  scope is too limited and doesn’t encompass the full breadth of what falls under the definition of purchased services. The fact is, there are over 250 clinical services that are categorized as a purchased service including pharmacy compounding…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

When providers think of purchased services, their minds typically go to facility support, IT, and ancillary services. However, this scope is too limited and doesn’t encompass the full breadth of what falls under the definition of purchased services. The fact is, there are over 250 clinical services that are categorized as a purchased service including pharmacy compounding services, dialysis services, imaging services, and neurology services.

Another way to describe this is to say that all “clinical services” could potentially be a purchased service, but are not necessarily the the most commonly known purchased services categories such as lawn care, medical waste disposal, or courier services that hospital administrators typically outsource. Because clinical services can be performed by skilled clinicians within the hospital, it can be challenging for healthcare organization leaders to determine whether or not outsourcing these types of services will affect quality of care and ultimately the total costs to serve patients.

Let’s take a closer look at the items found under the “clinical services” umbrella and identify both the questions to ask and typical tasks to perform to determine whether or not they should be outsourced. As with all decisions involving purchased services, but perhaps even more so with services that fall under the clinical category, the goal of choosing to outsource, is to help your healthcare organization save money while continuing to provide the high standard of care your patients expect.

  1. Start by comparing costs: Clinical services, like other purchased services categories, must be either outsourced or performed by facility personnel. Many providers should begin by comparing department profit and loss versus an outsourced firm’s cost model to determine what makes the most sense for each given department. There will likely not be a one-size-fits-all
  1. Perform clinical oversight: Though other purchased services areas may need little oversight, clinical services that are outsourced will need regular and rigorous clinical oversight to ensure they run smoothly and consistently attain the desired results. Department leaders in clinical areas must perform regular analysis of an outsourced firm’s results to determine whether their costs and patient outcomes have changed. Incorporating these data points into regularly scheduled Value Analysis Team (VAT) meetings will ensure consistent quality and outcomes.
  1. Find out if your outsourced firm has best-in-class results:Providers that outsource clinical areas are attempting to obtain the scale and best practices of the outsourced firm. Therefore, it is imperative that clinical leaders and supply chain leaders leverage the data and scale of their outsourced firm to achieve best-in-class results and continuous improvement. Don’t settle for “good enough.”
  1. Schedule regular reviews: Setting an outsourced service on autopilot won’t yield stellar results. Partnering with the outsourced service provider to review optimization opportunities and key performance data will help with continuous improvement and determine that the value of outsourcing isn’t falling away over time.

Every year, hospitals in America waste more than $50 billion on healthcare purchased services—including clinical services. Uncover millions in savings easier and faster with Valify. Valify is the only 100% dedicated web-based solution that allows healthcare organizations to quickly identify, benchmark and track savings in hospital purchased services.

Read more at getvalify.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

AAO-HNSF hearing loss guideline moves audiograms and amplification into primary care

AAO-HNSF’s new age-related hearing loss guideline calls for screening adults starting at age 50 and escalating to otoscopy, audiogram, and appropriately fit amplification. It shifts hearing loss from “patient complaint” to a routine primary-care workflow. The pressure shows up in audiology capacity, referral design, and documentation standards.

  • 01Screening at age 50 becomes a repeatable workflow, so capacity planning shifts from episodic ENT referrals to steady primary-care volume, especially where annual wellness visits are a dominant access point.
  • 02The guideline’s escalation sequence, screen, otoscopy, audiogram, amplification, then cochlear implant candidacy evaluation, creates a measurable funnel that health systems can instrument in the EHR and manage like any other pathway.
  • 03Asymmetric loss remains a separate trigger for MRI in many settings, and 2026 pre-proof work using NHANES and SEER highlights why imaging criteria choices can swing scan volume, a budgeting and radiology access issue, not a clinical footnote.

Sep 7, 2026

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

Accenture will keep supporting Australia’s My Health Record under a new three-year contract. ADHA is moving the platform to a multi-supplier operating model. The shift raises questions about shared integration discipline, tooling, and accountability when changes hit production.

  • 01Multi-supplier delivery is spreading across national-scale health platforms, as ADHA's My Health Record shift shows, moving risk from vendor selection to integration, runbooks, and accountability.
  • 02GenAI model upgrades are arriving with healthcare-specific claims, but the procurement work moves to evidence, safety controls, and monitoring once models sit inside clinical workflows.
  • 03Embedded AI expands the cyber asset inventory problem: if teams cannot discover the AI components across endpoints and devices, they cannot reliably secure or audit them.

Sep 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512